High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients-Reference-Cited by-同舟云学术

High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients

Published:1999-07 Issue:7 Volume:10 Page:795-802
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cottu P.H.,Zelek L.,Extra J.M.,Espie M.,Mignot L.,Morvan F.,Marty M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/10/7/795/19477699/10-7-795.pdf

Reference33 articles.

1. Cancer statistics, 1997;Parker;CA Cancer J Clin,1997

2. Hormonal therapy and chemotherapy;Flamm-Honig,1996

3. Construction and validation of a pratical prognostic index for patients with metastatic breast cancer;Yamamoto;J Clin Oncol,1998

4. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with curability of leukemia;Skipper;Cancer Chemother Res,1964

5. Rationale for the use of alternating non-cross-resistant chemotherapy;Goldie;Cancer Treat Rep,1982

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC;Cancers;2020-09-17

2. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen;British Journal of Cancer;2014-02-25

3. Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers;The Oncologist;2010-03-01

4. Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy;European Journal of Cancer Care;2009-03

5. An original administration of ifosfamide given once every other week: a clinical and pharmacological study;Anti-Cancer Drugs;2008-03